China's Center for Drug Evaluation accepted Merck's application for respiratory syncytial virus or RSV drug Clesrovimab, according to Yicai Global's Thursday report.
The drug was designed to prevent RSV infections in newborns and infants, the report said.
The US Food and Drug Administration's review into the drug is expected to end by June 10. It was first submitted to the FDA in December 2024, the report said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.